SYN-1212-M001
SYN-1212-M005
SYN-1212-M010
102979-854EA
180
USD
InStock
102979-854
102979-856
102979-858
SP2509 ≥95%
SP2509
LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi.